(CRSP) Crispr Therapeutics - Ratings and Ratios
Beta Thalassemia Therapy, Sickle Cell Therapy, CAR T Cells, Diabetes Therapy
CRSP EPS (Earnings per Share)
CRSP Revenue
Description: CRSP Crispr Therapeutics
CRISPR Therapeutics AG is a gene editing company leveraging its CRISPR/Cas9 platform to develop innovative gene-based medicines for serious human diseases. The companys pipeline includes various therapeutic programs targeting hemoglobinopathies, CAR T cell therapies, and type 1 diabetes, with a focus on treating diseases with high unmet medical needs.
Key highlights of the companys pipeline include CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating transfusion-dependent beta-thalassemia and severe sickle cell disease, as well as investigational CAR T programs targeting glypican-3 (GPC3) for solid tumors. The company is also developing CAR T cell therapies, including CTX112 and CTX131, and in vivo gene editing therapies, such as CTX310 and CTX320, to address cardiovascular disease.
From a financial perspective, CRISPR Therapeutics AG has a market capitalization of approximately $4.9 billion USD, with a forward P/E ratio of 23.36. The companys return on equity (ROE) is currently negative, at -20.08%, indicating significant investment in research and development. To evaluate the companys performance, key performance indicators (KPIs) to monitor include: R&D expenses as a percentage of revenue, pipeline progress (e.g., number of programs in clinical trials, approval milestones), and cash burn rate.
Strategic partnerships with companies like Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics are crucial to CRISPR Therapeutics AGs success, as they provide access to new technologies, expertise, and potential revenue streams. The companys ability to execute on its pipeline and forge new partnerships will be critical to driving growth and delivering returns to shareholders.
CRSP Stock Overview
| Market Cap in USD | 6,310m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2016-10-19 |
CRSP Stock Ratings
| Growth Rating | 20.5% |
| Fundamental | 26.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 21.6% |
| Analyst Rating | 3.96 of 5 |
CRSP Dividends
Currently no dividends paidCRSP Growth Ratios
| Growth Correlation 3m | 41.6% |
| Growth Correlation 12m | 42.4% |
| Growth Correlation 5y | -72.9% |
| CAGR 5y | 10.19% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.16 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.33 |
| Sharpe Ratio 12m | -1.00 |
| Alpha | 20.10 |
| Beta | 1.835 |
| Volatility | 60.64% |
| Current Volume | 2580.7k |
| Average Volume 20d | 2521.7k |
| Stop Loss | 63.6 (-7.1%) |
| Signal | -0.46 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-467.8m TTM) > 0 and > 6% of Revenue (6% = 2.24m TTM) |
| FCFTA -0.16 (>2.0%) and ΔFCFTA -10.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4361 % (prev 936.5%; Δ 3425 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.16 (>3.0%) and CFO -324.8m > Net Income -467.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 16.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (87.1m) change vs 12m ago 2.53% (target <= -2.0% for YES) |
| Gross Margin -228.1% (prev 24.29%; Δ -252.4pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.71% (prev 8.59%; Δ -6.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.96 (EBITDA TTM -511.5m / Interest Expense TTM -66.6m) >= 6 (WARN >= 3) |
Altman Z'' -4.73
| (A) 0.80 = (Total Current Assets 1.73b - Total Current Liabilities 104.4m) / Total Assets 2.03b |
| (B) -0.84 = Retained Earnings (Balance) -1.71b / Total Assets 2.03b |
| (C) -0.24 = EBIT TTM -530.5m / Avg Total Assets 2.18b |
| (D) -5.35 = Book Value of Equity -1.70b / Total Liabilities 318.6m |
| Total Rating: -4.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.26
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -6.78% = -3.39 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda -0.04 = -2.50 |
| 6. ROIC - WACC (= -41.44)% = -12.50 |
| 7. RoE -25.25% = -2.50 |
| 8. Rev. Trend -9.82% = -0.74 |
| 9. EPS Trend 7.82% = 0.39 |
What is the price of CRSP shares?
Over the past week, the price has changed by -8.66%, over one month by +11.83%, over three months by +24.10% and over the past year by +39.65%.
Is Crispr Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CRSP is around 63.10 USD . This means that CRSP is currently overvalued and has a potential downside of -7.79%.
Is CRSP a buy, sell or hold?
- Strong Buy: 12
- Buy: 5
- Hold: 10
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the CRSP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 81.5 | 19% |
| Analysts Target Price | 81.5 | 19% |
| ValueRay Target Price | 73 | 6.6% |
Last update: 2025-10-16 02:29
CRSP Fundamental Data Overview
P/E Forward = 23.3645
P/S = 165.8381
P/B = 3.8706
P/EG = -0.2142
Beta = 1.835
Revenue TTM = 37.4m USD
EBIT TTM = -530.5m USD
EBITDA TTM = -511.5m USD
Long Term Debt = 215.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 36.1m USD (from shortTermDebt, last quarter)
Debt = 215.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 18.3m USD (from netDebt column, last quarter)
Enterprise Value = 4.80b USD (6.31b + Debt 215.5m - CCE 1.72b)
Interest Coverage Ratio = -7.96 (Ebit TTM -530.5m / Interest Expense TTM -66.6m)
FCF Yield = -6.78% (FCF TTM -325.6m / Enterprise Value 4.80b)
FCF Margin = -871.5% (FCF TTM -325.6m / Revenue TTM 37.4m)
Net Margin = -1252 % (Net Income TTM -467.8m / Revenue TTM 37.4m)
Gross Margin = -228.1% ((Revenue TTM 37.4m - Cost of Revenue TTM 122.6m) / Revenue TTM)
Gross Margin QoQ = -5478 % (prev -6548 %)
Tobins Q-Ratio = 2.37 (Enterprise Value 4.80b / Total Assets 2.03b)
Interest Expense / Debt = 8.26% (Interest Expense 17.8m / Debt 215.5m)
Taxrate = -0.62% (negative due to tax credits) (1.29m / -207.3m)
NOPAT = -533.8m (EBIT -530.5m * (1 - -0.62%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 16.61 (Total Current Assets 1.73b / Total Current Liabilities 104.4m)
Debt / Equity = 0.13 (Debt 215.5m / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = -0.04 (negative EBITDA) (Net Debt 18.3m / EBITDA -511.5m)
Debt / FCF = -0.06 (negative FCF - burning cash) (Net Debt 18.3m / FCF TTM -325.6m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = -23.05% (Net Income -467.8m / Total Assets 2.03b)
RoE = -25.25% (Net Income TTM -467.8m / Total Stockholder Equity 1.85b)
RoCE = -25.65% (EBIT -530.5m / Capital Employed (Equity 1.85b + L.T.Debt 215.5m))
RoIC = -28.81% (negative operating profit) (NOPAT -533.8m / Invested Capital 1.85b)
WACC = 12.63% (E(6.31b)/V(6.53b) * Re(12.78%) + D(215.5m)/V(6.53b) * Rd(8.26%) * (1-Tc(-0.01)))
Discount Rate = 12.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.47%
Fair Price DCF = unknown (Cash Flow -325.6m)
EPS Correlation: 7.82 | EPS CAGR: 90.33% | SUE: 2.70 | # QB: 1
Revenue Correlation: -9.82 | Revenue CAGR: 126.7% | SUE: -0.15 | # QB: 0
Additional Sources for CRSP Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle